TORG
20.8.2021 11:29:08 CEST | Business Wire | Press release
Cryptocurrencies seem to be the flavour of the season as increasingly more people around the world are embracing them; sometimes even abandoning their traditional avenues like Equity, Gold, etc. Though the concept of crypto (as they are informally called) investment seems novel, the first cryptocurrency came into the market more than a decade back. The reliable supply, decentralised control, swift success, and exorbitant returns given by cryptocurrencies have now allayed all fears of them being a ‘fad’ or even a ‘sham’. Today, you have many different options of cryptocurrencies trading on different real-time online platforms.
Though, as the cryptocurrencies do not have any underlying asset to base your buying or selling decision upon (for example – Google shares move on the performance of the Google companies), all the cryptocurrencies on the face look similar. But, one cryptocurrency, recently launched, is destined to change all that, and is already making waves around the world as people are lapping it up in droves.
TORG is the world’s first sustainability driven, completely decentralized, and utility-focused cryptocurrency, aimed at global human development. If it sounds confusing, it’s because it’s such a new concept. As the world’s first utilimeme, it combines the power of meme-driven popularity with the sustainability that comes with a focus on global utility.
Launched recently on 20th July 2021, TORG has already reached the maximum supply of 777 billion and its current circulating supply is 100%. TORG is secured as an ERC-20 token on the Ethereum blockchain. It is not open to pausing, minting, and mining. Being extremely secure and stable, TORG’s smart contract is audited by the best in the industry blockchain security and infrastructure leader Certik.
TORG started trading from 20th July 2021 on world’s leading Global Exchanges, namely Uniswap , BitMart , CoinTiger , ProBit , CoinsBit Global , CoinsBit India , WhiteBit , HotBit.io , LA Token , IndoEx International , Bilaxy , etc. It is expanding its reach rapidly and is expected to be available on many trading platforms, big & small, shortly. Since the launch, different pairs of TORG have been added by the centralized exchanges, including TORG/USDT, TORG/BTC, and TORG/ETH .
TORG – It is different, but is it better?
What makes TORG better than other cryptocurrencies is the same thing that makes the world a better place to live in, i.e. focus on sustainability. TORG is not just any regular cryptocurrency. It is the world’s first cryptocurrency that has sustainability & utility as its underlying core assets. It aims to increase commercial & business activities, generate growth & employment opportunities for the world’s youth, develop eco-friendly infrastructure around the world, push the population to adopt green initiatives, and alleviate the economic constraints facing the world’s marginalized demographic sections.
About TORG
TORG Foundation is the force behind this intuitive & innovative cryptocurrency that aims to disrupt the crypto market forever. With the mission & vision of helping the society keep its carbon footprint to the minimum while increasing the economic activities both in developing & developed countries for the holistic development of mankind, the foundation keeps the interests of humanity and mankind at the core of all its decisions.
To maintain the full transparency of transactions, TORG is completely decentralised, and the foundation does not & cannot decide or predict its price movements.
It’s #TORGTime.
For more information and updates, visit www.torg.to or follow TORG on Twitter , Telegram , Facebook , and Medium .
Disclaimer: The information available on this article is for educational purposes only and not an offer, solicitation of an offer, or advice to buy or sell securities, investment or tax advice. Purchasing cryptocurrencies comes with a number of risks. All Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made here. The data and non-TORG names are for informational and identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005103/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom